

## Vietnam Support for Pentavalent Vaccine

### This Decision Letter sets out the Programme Terms

<b>1. Country:</b> Vietnam			
<b>2. Grant number:</b> 1719-VNM-04a-X/ 08-VNM-08c-Y / 18-VNM-04g-Y			
<b>3. Date of Decision Letter:</b> 8 March 2019			
<b>4. Date of the Partnership Framework Agreement (PFA):</b> 9 October 2013			
<b>5. Programme title:</b> New Vaccine Support (NVS), Pentavalent Routine			
<b>6. Vaccine type:</b> Pentavalent			
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 1 dose(s) per vial, LIQUID			
<b>8. Programme duration<sup>1</sup>:</b> 2009 -2019			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the PFA, if applicable)			
	<b>2009-2018</b>	<b>2019</b>	<b>Total<sup>2</sup></b>
Programme Budget (US\$)	88,428,871	716,000	89,144,871
<b>10. Vaccine introduction grant (in US\$):</b> paid US\$ 492,500 on 23 September 2008			
<b>11. Product switch grant:</b> US\$113,345 disbursed on 7/8/2018			
<b>12. Indicative Annual Amounts:</b> (subject to the terms of the PFA, if applicable) <sup>3</sup>			
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2009-2018</b>	<b>2019</b>	
Number of Pentavalent vaccines doses		638,700	
Annual Amounts (US\$)	88,428,871	716,000	
<b>13. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
<b>14. Self-procurement:</b> Not applicable			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the amount that Gavi has approved.

<p><b>15. Co-financing obligations:</b> Reference code: 1719-VNM-04a-X-C</p> <p>According to the co-financing policy, the Country falls within the group Accelerated Transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>															
<table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2019</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>5,036,200</td> </tr> <tr> <td>Number of AD syringes</td> <td>5,294,900</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td></td> </tr> <tr> <td>Number of safety boxes</td> <td>58,275</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>5,287,990</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>5,883,000</td> </tr> </tbody> </table>	Type of supplies to be purchased with Country funds in each year	2019	Number of vaccine doses	5,036,200	Number of AD syringes	5,294,900	Number of re-constitution syringes		Number of safety boxes	58,275	Value of vaccine doses (US\$)	5,287,990	Total co-financing payments (US\$) (including freight)	5,883,000	
Type of supplies to be purchased with Country funds in each year	2019														
Number of vaccine doses	5,036,200														
Number of AD syringes	5,294,900														
Number of re-constitution syringes															
Number of safety boxes	58,275														
Value of vaccine doses (US\$)	5,287,990														
Total co-financing payments (US\$) (including freight)	5,883,000														
<p><b>16. Operational support for campaigns:</b> Not applicable</p>															
<p><b>17. Additional reporting requirements:</b> Not applicable</p> <table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td> <p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock, by end March;</li> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul> </td> <td> <p>31 March 2019</p> <p>15 May 2019</p> </td> </tr> <tr> <td> <p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p> </td> <td> <p>To be agreed with Secretariat</p> </td> </tr> </tbody> </table>			Due dates	<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock, by end March;</li> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 2019</p> <p>15 May 2019</p>	<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Secretariat</p>								
	Due dates														
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock, by end March;</li> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 2019</p> <p>15 May 2019</p>														
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Secretariat</p>														
<p><b>18. Financial clarifications:</b> Not applicable</p>															
<p><b>19. Other conditions:</b> The 2019 shipment will take place only after the confirmation of the deployment of the 2018 Pentavalent Gavi funded vaccines throughout the country.</p>															

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman

Managing Director, Country Programmes

8 March 2019